Copyright
©The Author(s) 2025.
World J Diabetes. May 15, 2025; 16(5): 104576
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.104576
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.104576
Table 1 General characteristics of the study subjects
Variables1 | Nondiabetic group | Type 2 diabetic group | ||
n | % | n | % | |
Demographics | ||||
Age (years) | ||||
< 50 | 433720 | 66.86 | 13991 | 42.16 |
≥ 50 | 215026 | 33.14 | 19193 | 57.84 |
mean ± SD | 49.56 | 7.79 | 55.34 | 10.16 |
Sex | ||||
Women | 391920 | 60.41 | 14853 | 44.76 |
Men | 256826 | 39.59 | 18331 | 55.24 |
SBP (mmHg) | ||||
< 130 | 408227 | 62.93 | 14018 | 42.24 |
≥ 130 | 240519 | 37.07 | 19166 | 57.76 |
mean ± SD | 125.00 | 18.65 | 133.50 | 18.67 |
DBP (mmHg) | ||||
< 85 | 465778 | 71.80 | 21673 | 65.31 |
≥ 85 | 182968 | 28.20 | 11511 | 34.69 |
mean ± SD | 78.44 | 12.71 | 80.98 | 11.98 |
Medications | ||||
Anti-diabetic agents | 0 | 0.00 | 33184 | 100.00 |
Antihypertensive agents | 142453 | 21.96 | 21489 | 64.76 |
Antilipid agents | 35626 | 5.49 | 19710 | 59.40 |
Laboratory results | ||||
FPG (mg/dL) | ||||
< 126 | 648746 | 100.00 | 8319 | 25.07 |
≥ 126 | 0 | 0 | 24865 | 74.93 |
mean ± SD | 91.94 | 10.85 | 170.00 | 70.75 |
TC (mg/dL) | ||||
< 200 | 348098 | 53.66 | 22169 | 66.81 |
≥ 200 | 300648 | 46.34 | 11015 | 33.19 |
mean ± SD | 199.00 | 37.63 | 187.00 | 45.14 |
HDL-C (mg/dL) | ||||
M: > 40; F > 50 | 471424 | 72.67 | 17571 | 52.95 |
M: ≤ 40; F ≤ 50 | 177322 | 27.33 | 15613 | 47.05 |
mean ± SD | 56.04 | 16.69 | 47.73 | 15.91 |
TG (mg/dL) | ||||
< 150 | 470029 | 72.45 | 17411 | 52.47 |
≥ 150 | 178717 | 27.55 | 15773 | 47.53 |
mean ± SD | 134.60 | 126.40 | 196.20 | 223.70 |
ALT (IU/L) | ||||
Normal | 539660 | 83.19 | 24258 | 73.10 |
Above normal | 109086 | 16.81 | 8.926 | 26.90 |
mean ± SD | 25.86 | 31.40 | 31.76 | 34.01 |
AST (IU/L) | ||||
Normal | 579562 | 89.34 | 27350 | 82.42 |
Above normal | 69184 | 10.66 | 5834 | 17.58 |
mean ± SD | 24.51 | 23.81 | 26.88 | 25.83 |
Metabolic dysfunctions | ||||
Obesity, kg/m2 | ||||
BMI ≤ 30 | 600060 | 92.50 | 26247 | 79.10 |
BMI > 30 | 48686 | 7.5 | 6937 | 20.90 |
Hypertension | ||||
No | 370062 | 57.04 | 12457 | 37.54 |
Yes | 278684 | 42.96 | 20727 | 62.46 |
Dyslipidemia | ||||
No | 207416 | 31.97 | 8227 | 24.79 |
Yes | 441330 | 68.03 | 24957 | 75.21 |
Personal history | ||||
Regular exercise | ||||
No | 359624 | 55.43 | 17272 | 52.05 |
Yes | 289122 | 44.57 | 15912 | 47.95 |
Outcomes | ||||
Cirrhosis of liver | 2697 | 0.42 | 385 | 1.16 |
Hepatic complications | 1436 | 0.22 | 207 | 0.62 |
HCC | 803 | 0.12 | 183 | 0.55 |
Hepatic mortality | 517 | 0.08 | 134 | 0.40 |
Mean follow-up period (years) (± SD) | 6.59 | 2.36 | 6.78 | 2.45 |
Total | 648746 | 100.00 | 33184 | 100.00 |
- Citation: Chen HF, Chang YY, Chen P, Shen XH, Chang CH, Hsu WL. Risks of liver cirrhosis, hepatocellular carcinoma, hepatic-related complications, and mortality in patients with type 2 diabetes in Taiwan. World J Diabetes 2025; 16(5): 104576
- URL: https://www.wjgnet.com/1948-9358/full/v16/i5/104576.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i5.104576